Securities Code: 301093
Securities Abbreviation: Hualan Shares
Announcement No.: 2026-064
Jiangsu Hualan Pharmaceutical New Material Co., Ltd.
Announcement on the Completion of Share Reduction Plan by Some Directors and Senior Management
The Company's Director, Deputy General Manager Mr. Xiao Feng guarantees that the information provided to the Company is true, accurate, and complete, and contains no false records, misleading statements, or major omissions.
The Company and all members of the Board of Directors guarantee that the content of this announcement is consistent with the information provided by the information disclosure obligor.
On June 23, 2026, Jiangsu Hualan Pharmaceutical New Material Co., Ltd. (hereinafter referred to as the "Company" or "Hualan Shares") disclosed the "Pre-disclosure Announcement on Share Reduction Plan by Some Directors and Senior Management of the Company" (Announcement No.: 2026-052) on the Juchao Information Network. Director and Deputy General Manager Mr. Xiao Feng planned to reduce his holdings of the Company's shares by no more than 72,800 shares within three months from the 15th trading day after the announcement of the reduction plan (from July 15, 2026, to October 14, 2026, no reduction during the window period, hereinafter referred to as the same), which is no more than 0.04% of the total share capital after excluding shares in the dedicated repurchase securities account.
On July 8, 2026, the Company disclosed the "Implementation Announcement of 2025 Annual Equity Distribution" (Announcement No.: 2026-055) on the Juchao Information Network. The Company's 2025 annual equity distribution plan is as follows: based on 163,869,265 shares (the Company's total share capital of 163,970,594 shares minus 101,329 shares held in the dedicated repurchase securities account), it is proposed to distribute a cash dividend of RMB 0.5 per 10 shares (tax inclusive) to all shareholders, totaling RMB 8,193,463.25 (tax inclusive), with no bonus shares issued. The undistributed profits will be carried forward to subsequent years. Capital reserve will be used to transfer 3 shares for every 10 shares to all shareholders, totaling 49,160,779 shares to be transferred. After the completion of this capital reserve transfer, the Company's total share capital will increase to 213,131,373 shares. The equity registration date for this equity distribution is July 15, 2026, and the ex-rights and ex-dividend date is July 16, 2026. The first trading day for unrestricted tradable shares transferred (bonus shares) in this distribution is July 16, 2026. As of the disclosure date of this announcement, the Company's 2025 annual equity distribution has been completed. The Company's total share capital has increased from 163,970,594 shares to 213,131,373 shares. Due to the above reasons, as of July 15, 2026, the number of shares held by Mr. Xiao Feng in the Company increased from 291,200 shares to 378,560 shares.
According to the "Guiding Opinions on Share Reductions by Shareholders, Directors, and Senior Management of Listed Companies" issued by the Shenzhen Stock Exchange, if the shares held by directors and senior management increase due to equity distribution by the listed company, the number of shares transferable in the current year can be increased proportionally.
According to Mr. Xiao Feng's share reduction plan, if events such as bonus share issuance or capital reserve transfer occur during the implementation of the reduction plan, the number of shares to be reduced will be adjusted accordingly. Therefore, the number of shares to be reduced by Mr. Xiao Feng has been adjusted from no more than 72,800 shares to no more than 94,640 shares. Apart from the adjustment for the aforementioned reasons, there are no other adjustments to Mr. Xiao Feng's share reduction plan.